A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities

BACKGROUND: Little data exist on antifibrotic drugs for treating symptomatic patients with persistent interstitial lung abnormalities in the postacute phase of coronavirus disease 2019 (COVID-19). Herein, we describe the physician practices of prescribing pirfenidone and nintedanib for these patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhooria, Sahajal, Maturu, Venkata Nagarjuna, Talwar, Deepak, Kumar, Sachin, Handa, Ajay, Agrawal, Priya Nath, Jindal, Aditya, Tampi, PS, Goyal, Abhishek, Maskey, Dipesh, Aggarwal, Ashutosh Nath, Behera, Digambar, Jindal, Surinder Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200209/
https://www.ncbi.nlm.nih.gov/pubmed/35488683
http://dx.doi.org/10.4103/lungindia.lungindia_568_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200209/
https://www.ncbi.nlm.nih.gov/pubmed/35488683
http://dx.doi.org/10.4103/lungindia.lungindia_568_21

Ejemplares similares